RESEARCH ALERT - UBS rates Centocor a buy . - - UBS Securities said analyst Tim Wilson initiated coverage of Centocor Inc with a buy rating and a 12 - month price target of $ 41 . - - In a report , the analyst said the company ' s anti - blood clot drug ReoPro , sold by partner Eli Lilly and Co , could be " one of the best selling products the biotechnology industry has yielded . " - - The commercial potential of Centocor ' s CenTNF in Crohn ' s disease is " substantial , " the analyst said . - - The stock was up 3 / 4 to 26 - 3 / 4 in early trading . 
